| __timestamp | Amphastar Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 28427000 | 51796000 |
| Thursday, January 1, 2015 | 37065000 | 72758000 |
| Friday, January 1, 2016 | 41199000 | 61008000 |
| Sunday, January 1, 2017 | 43415000 | 66962000 |
| Monday, January 1, 2018 | 57564000 | 84888000 |
| Tuesday, January 1, 2019 | 68853000 | 107068000 |
| Wednesday, January 1, 2020 | 67229000 | 122964000 |
| Friday, January 1, 2021 | 60932000 | 208808000 |
| Saturday, January 1, 2022 | 74771000 | 253297000 |
| Sunday, January 1, 2023 | 73741000 | 216566000 |
Igniting the spark of knowledge
In the ever-evolving world of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated significant commitment to R&D, with BioCryst consistently outpacing Amphastar. From 2014 to 2023, BioCryst's R&D expenses surged by approximately 318%, peaking in 2022. In contrast, Amphastar's R&D investment grew by about 160% over the same period. This trend underscores BioCryst's aggressive pursuit of groundbreaking therapies, particularly in the realm of rare diseases. Meanwhile, Amphastar's steady growth reflects a more measured approach, focusing on incremental advancements. As the industry continues to face challenges and opportunities, these companies' R&D strategies will be pivotal in shaping their future trajectories. The data highlights the critical role of sustained investment in R&D for driving innovation and maintaining competitive advantage in the biopharmaceutical sector.
R&D Insights: How Novo Nordisk A/S and Amphastar Pharmaceuticals, Inc. Allocate Funds
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Amphastar Pharmaceuticals, Inc.
R&D Insights: How Regeneron Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. Allocate Funds
R&D Insights: How Dr. Reddy's Laboratories Limited and BioCryst Pharmaceuticals, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alkermes plc and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amicus Therapeutics, Inc. and Amphastar Pharmaceuticals, Inc.
R&D Spending Showdown: Vericel Corporation vs BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and BioCryst Pharmaceuticals, Inc.